CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time.
A live webcast of Ironwood’s presentation and the question and answer session will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
(NASDAQ: IRWD) is a commercial biotechnology company focused on creating
medicines that make a difference for patients, building value for our
fellow shareholders, and empowering our passionate team. We are
commercializing two innovative primary care products: linaclotide, the
U.S. branded prescription market leader for adults with irritable bowel
syndrome with constipation (IBS‐C) or chronic idiopathic constipation
(CIC), and lesinurad, which is approved to be taken with a xanthine
oxidase inhibitor (XOI), or as a fixed-dose combination with
allopurinol, for the treatment of hyperuricemia associated with gout. We
are also advancing a pipeline of innovative product candidates in areas
of significant unmet need, including uncontrolled gastroesophageal
reflux disease, diabetic nephropathy, heart failure with preserved
ejection fraction, achalasia and sickle cell disease. Ironwood was
founded in 1998 and is headquartered in Cambridge, Mass. For more
information, please visit www.ironwoodpharma.com
or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180102005502/en/
